Basal Cell Carcinoma/InflammationBasal Cell CarcinomaBasal cell carcinoma (BCC) is the most common form of human cancer. At present the average age of patients is 60, however, there is also a clear trend towards manifestation in younger patients. BCC mostly affects the sun exposed head and neck regions of the body and is a skin malignancy which can locally invade through deeper structures. Tumours arise in the basal cells of the epidermis. Although classified as a malignant lesion BCC rarely metastasises. Typically these basal cell tumours enlarge slowly and relentlessly with a tendency to be locally destructive. There are various types of BCC, based on histological differentiation patterns: The occurrence of mixed types is also very common.InflammationInflammation is the body's immune systems response to injury, disease or foreign substances and is characterised by swelling, redness, heat and/or pain. Whilst this response is vital in protecting the body against infectious agents, such as bacteria and viruses, regulation of this process sometimes goes array causing inflammation when foreign substances are absent, thus resulting in injury to the body's own tissue. Inflammation is now known to play a role in many of the most commonly diagnosed diseases of today. Patients suffering from such diseases would therefore benefit from therapeutic approaches that reinstall the immunological balance and keep over-active immune cells under control. HDAC inhibitors, which work by altering levels of gene transcription, have been shown to regulate several key processes involved in the inflammatory response. There are a number of inflammatory skin disorders which, according to these findings, could potentially benefit from a topical treatment based on the novel therapeutic principle of HDAC inhibition. Useful links :
Pipeline
- Baceca^®